Xoma Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Berkeley CA United States (1981)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2002
NCT00034203
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Alternative names

XOMA (US) LLC

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 2)

Adenocarcinoma (Phase 1)

Arthritis (Phase 2)

Arthritis, Psoriatic (Phase 1)

Arthritis, Rheumatoid (Phase 2)

Behcet Syndrome (Phase 3)

Congenital Hyperinsulinism (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetes Mellitus, Type 2 (Phase 2)

Ear Diseases (Phase 2)

Graft vs Host Disease (Phase 2)

Hodgkin Disease (Phase 2)

Hyperinsulinism (Phase 2)

Hypoglycemia (Phase 2)

Labyrinth Diseases (Phase 2)

Labyrinthitis (Phase 2)

Leukemia (Phase 1)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 1)

Leukemia, Lymphoid (Phase 1)

Lymphoma (Phase 2)

Osteoarthritis (Phase 2)

Pyoderma (Phase 3)

Pyoderma Gangrenosum (Phase 3)

Uveitis (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 28
  • # of Trial APIs: 11